© 1996 American Heart Association, Inc.
Articles |
Hormone Replacement Therapy Lowers Plasma Lp(a) Concentrations
Comparison of Cyclic Transdermal and Continuous Estrogen-Progestin Regimens
the Department of Medicine, University of Helsinki, Helsinki (M.-R.T., S.L.); the Department of Obstetrics and Gynecology, Central Hospital of Jyvaskyla, Jyvaskyla (J.P.); Gyne-Praxis, Jyva-skyla (T.P., H.L.); Central Hospital of Northern Carelia, Joensuu; Iisalmi District Hospital, Iisalmi (M.B.); and the National Public Health Institute, Helsinki (J.K., C.E.), Finland.
Correspondence to Prof Marja-Riitta Taskinen, MD, Department of Medicine, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.
To study the responses of serum lipoproteins, apoproteins (apo's), and lipoprotein(a) (Lp[a]) to two frequently used hormone replacement therapies (HRTs), 120 postmenopausal women were randomly allocated to receive either transdermal therapy consisting of 28-day cycles with patches that delivered 17ß-estradiol (50 µg/d) combined with cyclic oral medroxyprogesterone acetate (10 mg/d for 12 days per cycle) or continuous oral 17ß-estradiol (2 mg/d) together with norethisterone acetate (1 mg/d) for 12 months. Blood samples were taken before and at 6 and 12 months of HRT. Concentrations of serum total, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol decreased by 14% (P<.001), 17% (P<.001), and 9% (P<.001) in the oral HRT group. Respective changes were 5.7% (P<.001), 4.8% (P<.05), and 4.7% (NS) in the transdermal group. Serum triglycerides remained unchanged in the oral group but decreased by 15.7% (P<.001) in the transdermal group. We observed only trivial changes in serum apo B levels. The changes in apo A-I levels paralleled those of HDL cholesterol in the oral HRT group. The concentration of serum Lp(a) decreased by 31% (P<.001) and 16% (P<.001) in the two groups. The combination of progestin and transdermal estrogen was not associated with any further change of Lp(a). The decrement in Lp(a) during therapy was positively associated with baseline Lp(a) levels in both groups (r=.96, P<.001 and r=.88, P<.001). Thus, both HRT regimens were highly effective in lowering elevated Lp(a) levels in postmenopausal women. The divergent responses of LDL and HDL cholesterol in the two HRT groups may influence the potential cardioprotective effects of the two HRT regimens. Prospective trials are needed to define the long-term effects with respect to coronary heart disease risk.
Key Words: hormone replacement therapy • lipoprotein(a) • postmenopause • LDL cholesterol • HDL cholesterol
This article has been cited by other articles:
 |
|
 |
|
  E. L. Ding, Y. Song, J. E. Manson, D. J. Hunter, C. C. Lee, N. Rifai, J. E. Buring, J. M. Gaziano, and S. Liu Sex Hormone-Binding Globulin and Risk of Type 2 Diabetes in Women and Men N. Engl. J. Med., September 17, 2009; 361(12): 1152 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suk Danik, N. Rifai, J. E. Buring, and P. M. Ridker Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events J. Am. Coll. Cardiol., July 8, 2008; 52(2): 124 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Davison and S. R. Davis New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2470 - 2478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Schaefer Lipoproteins, nutrition, and heart disease Am. J. Clinical Nutrition, February 1, 2002; 75(2): 191 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Alexandersen, B. J. Riis, and C. Christiansen Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3013 - 3020. [Abstract] [Full Text]
|
|
|
|
|
|
E. Sbarouni, Z. S. Kyriakides, and D. T. Kremastinos The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1244 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Su, H. Campos, H. Judge, B. W. Walsh, and F. M. Sacks Metabolism of Apo(a) and ApoB100 of Lipoprotein(a) in Women: Effect of Postmenopausal Estrogen Replacement J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3267 - 3276. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. A. Enas and K. Orth-Gomer Lipoprotein(a) as a Determinant of Coronary Heart Disease in Young Women: A Stronger Risk Factor Than Diabetes? • Response Circulation, January 27, 1998; 97(3): 293 - 295. [Full Text]
|
|
|
|
|
|
V. Mijatovic, P. Kenemans, J. C. Netelenbos, E. R. A. Peters-Muller, G. J. van Kamp, G. A. Voetberg, P. H. M. van de Weijer, and M. J. van der Mooren Oral 17{beta}-Estradiol Continuously Combined with Dydrogesterone Lowers Serum Lipoprotein(a) Concentrations in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3543 - 3547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Tuck, S. Holleran, and L. Berglund Hormonal Regulation of Lipoprotein(a) Levels: Effects of Estrogen Replacement Therapy on Lipoprotein(a) and Acute Phase Reactants in Postmenopausal Women Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1822 - 1829. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. W. F. Wilson and W. B. Kannel Should We Measure Lipoprotein Lp(a)? Arch Intern Med, June 9, 1997; 157(11): 1161 - 1162. [Abstract] [PDF]
|
|